↓ Skip to main content

A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in…

Overview of attention for article published in BMC Pharmacology and Toxicology, July 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients
Published in
BMC Pharmacology and Toxicology, July 2022
DOI 10.1186/s40360-022-00599-x
Pubmed ID
Authors

Reza Safaei Nodehi, Behjat Kalantari, Jahangir Raafat, Nafiseh Ansarinejad, Vahid Moazed, Seyed Mohammad Reza Mortazavizadeh, Mehran Hosseinzadeh, Bayazid Ghaderi, Arash Jenabian, Mojtaba Qadyani, Shirin Haghighat, Abolghasem Allahyari, Mehrzad Mirzania, Mohammad Seghatoleslami, Mehrdad Payandeh, Afsaneh Alikhasi, Hamidreza Kafi, Farhad Shahi

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Professor 3 18%
Lecturer 2 12%
Student > Bachelor 2 12%
Researcher 2 12%
Professor > Associate Professor 1 6%
Other 1 6%
Unknown 6 35%
Readers by discipline Count As %
Medicine and Dentistry 4 24%
Nursing and Health Professions 3 18%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Neuroscience 1 6%
Business, Management and Accounting 1 6%
Other 0 0%
Unknown 7 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 July 2022.
All research outputs
#20,433,667
of 22,986,950 outputs
Outputs from BMC Pharmacology and Toxicology
#368
of 442 outputs
Outputs of similar age
#342,499
of 431,668 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#3
of 9 outputs
Altmetric has tracked 22,986,950 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 442 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 431,668 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.